


Patent Application 10/800,328
 Attorney Docket No. PC25322A

3

Amendment to the Specification

Please replace the paragraph at page 2, lines 19-23 with the following:

or the (R) or (S) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof or of any of the foregoing, wherein m is 0 or 1; Z is




wherein R^7 is hydrogen or (C₁-C₃)alkoxy; R^8 is hydrogen, hydroxy, or (C₁-C₃)alkoxy; and R^9 is (C₁-C₃)alkyl[[oxy]];

Patent Application 10/800,328
Attorney Docket No. PC25322A

4

Please replace the paragraph at Page 3, line 21 spanning to page 4, line 3 with the following:

or the (R) or (S) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof or of any of the foregoing, wherein Z is




wherein R⁷ is hydrogen or (C₁-C₃)alkoxy; R⁸ is hydrogen, hydroxy, or (C₁-C₃)alkoxy; and R⁹ is (C₁-C₃)alkyl[[oxy]];

Patent Application 10/800,328
Attorney Docket No. PC25322A

5

Please replace the paragraph at page 14, lines 16-20 with the following:

as a racemate, or the (R) and (S) enantiomers thereof, or the *cis* and *trans* isomers thereof,
wherein X is oxygen or NR, wherein R is hydrogen or (C₁-C₆)alkyl;
R¹ and R² are each independently as hereinbefore defined and



wherein R⁷ is hydrogen or (C₁-C₃)alkoxy; R⁸ is hydrogen, hydroxy, or (C₁-C₃)alkoxy; and R⁹ is (C₁-C₃)alkyl[[oxy]].